MZL and ASCT
The aim of this study was to determine the outcome in patients with either relapsed or refractory marginal zone lymphoma (MZL) undergoing autologous stem cell transplantation.
Results were presented at the 2014 American Society of Hematology annual meeting. Patients (n = 111) had nodal, extranodal (MALT) MZL, 55 patients had nodal MZL and 33 patients had splenic MZL. Five-year event-free survival (EFS) and overall survival (OS) were 53% (95% CI 45-61%) and 73% (95% CI 65-79%), respectively.
Multivariate analysis showed that those older than 65 years had both a shorter EFS and OS (HR = 8.6, 95% CI 2.8-26.2, p<0.001; HR = 5.2, 95% CI 1.9-14, p = 0.001, respectively). As well, MZL predicted a shorter OS than MALT (HR = 3.2, 95% CI 1.2-8.7, p = 0.023).
Click here for the full article.